CHARLOTTE, N.C.–(BUSINESS WIRE)–Original Glazed® is getting a Halloween glow-up! Starting today, Krispy Kreme is putting a festive twist on its iconic doughnut with orange-colored dough in the new All Jacked Up Dozen, available for just $13 through Thursday. It’s the same melt-in-your-mouth Original Glazed® taste guests know and love, now dressed up for Halloween. And don’t worry, the classic Original Glazed® isn’t going anywhere! But the treats don’t stop there. On Friday and Saturday (Oct.

NEW YORK–(BUSINESS WIRE)–New Mountain Finance Corporation (NASDAQ: NMFC) (“NMFC” or “the Company”) today announced that on October 20, 2026, the Company’s board of directors authorized an extension of a previously established stock repurchase program (the “Repurchase Program”). Pursuant to the Repurchase Program, the Company can repurchase up to $150 million worth of its common stock at the discretion of NMFC’s management team. The Repurchase Program was set to expire on December 31, 2026, bu

NEW YORK–(BUSINESS WIRE)–OpenAI’s newly released GPT-6.1 Terra scored 78.2% on the DualEntry Accounting AI Benchmark, tying for 18th among 22 leading AI models tested. The model performed strongest in transaction classification and journal entries. But weaker results in accounts payable and accounts receivable left it behind Google’s Gemini 4 Argon at 91.1%, Zhipu AI’s GLM-5.3 Flash at 88.1% and SpaceXAI’s Grok 4.7 at 88.1%. It also trails OpenAI’s own GPT-6.1 Sol, which scored 81.2%. Where T

NEW YORK–(BUSINESS WIRE)–North Haven Private Income Fund LLC (“PIF”) and North Haven Private Income Fund A LLC (“PIF A” and each of PIF and PIF A, a “Company” and together, the “Companies”), each a business development company externally managed by MS Capital Partners Adviser Inc. (the “Adviser”), announced today that PIF has entered into a merger agreement with PIF A (the “Merger Agreement”), pursuant to which PIF A would merge with and into PIF (the “Merger”) with Class I unitholders of PIF

HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 10,650 shares of the Company’s common stock at an exercise price per share of $18.54, which was the closing price

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in the following upcoming investor conferences on Nov. 9, 2026:8th Annual Wolfe Research Healthcare Conference in New York CityGuggenheim Securities 3rd Annual Healthcare Innovation Conference in BostonFireside chat: 3 p.m. ETThe presentation from the Guggenheim conference will be webcast live under the in

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.